Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated informed consent prior to any study specific procedures.~* Males or females aged 18 to 80 years, inclusive, at Screening~* Females must be non-pregnant, non-lactating and either be post-menopausal for at least -2 months, have documentation of irreversible surgical sterilization, use of acceptable -contraceptive method, or sexual abstinence, or a sterile sexual partner from Screening -until 30 days after the last subject visit.~* Males must agree to avoid fathering a child (or donating sperm), and therefore be either sterile (documented) or agree to use approved methods of contraception, from the time of enrollment until 30 days after end of study.~* Chronic maintenance hemodialysis (HD) 3x/week for at least 3 months or chronic maintenance peritoneal dialysis (PD) for a minimum of 6 months.~* If receiving active vitamin D or calcimimetics, the dose should have been unchanged for the last 4 weeks prior to Screening.~* Kt/V ≥1.2 at most recent measurement prior to Screening.~* Prescribed and taking phosphate binder medication at least 3 times per day, and the prescribed dose should have been unchanged during the last 4 weeks prior to Screening.~* Serum phosphorus levels must be ≥5.5 and ≤10.0 mg/dL at Screening and the end of the run-in period, analyzed at the central laboratory used in the study.~Exclusion Criteria:~* Severe hyperphosphatemia defined as having an s-P level \>10.0 mg/dL on phosphate-binders at any time point during routine clinical monitoring for the 3 preceding months before Screening.~* Serum/plasma parathyroid hormone \>1200 pg/mL.~* Clinical signs of hypovolemia at Screening as judged by the Investigator.~* History of inflammatory bowel disease (IBD) or irritable bowel syndrome with diarrhea (IBS-D).~* Scheduled for living donor kidney transplant or plans to relocate to another center during the study period.~* Use of an investigational agent within 30 days prior to Screening.~* Involvement in the planning and/or conduct of the study (applies to both Ardelyx/Contract Research Organization (CRO) staff and/or staff at the study site).~* If, in the opinion of the Investigator, the subject is unable or unwilling to fulfill the requirements of the protocol or has a condition which would render the results uninterpretable.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tenapanor 30 mg BID (Type: EXPERIMENTAL): During the Double-Blind Treatment Period, subjects will receive tenapanor starting at a dose of 30 mg bid (three 10 mg tablets each time).~Investigators may decrease or increase the dose of study medication based on s-P levels and/or gastrointestinal (GI) tolerability in 10 mg increments to a minimum of 10 mg bid or a maximum of 30 mg bid at any time during the Double-Blind Treatment Period.
- Placebo (Type: PLACEBO_COMPARATOR): same size, weight and appearance of experimental drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete